Home / Technology / AI Startup Triomics Secures $22M for Oncology Data Automation
AI Startup Triomics Secures $22M for Oncology Data Automation
28 May
Summary
- Triomics uses AI to automate heavy data tasks for oncologists.
- The startup secured $22 million in Series B funding led by Battery Ventures.
- AI summaries help reduce appointment prep time, freeing up oncologists.
Triomics, a company developing an AI-powered platform to automate data-intensive tasks in oncology, has announced a $22 million Series B funding round. The financing was spearheaded by Battery Ventures and included contributions from existing investors such as Nexus Venture Partners and Lightspeed Venture Partners.
Founded in 2021, Triomics initially focused on aiding oncologists in identifying suitable clinical trials. As AI capabilities advanced, the startup expanded its platform to include verifiable patient summaries within existing clinician workflows, thereby reducing the significant time spent preparing for appointments. This efficiency gain is crucial in oncology, where complex patient histories and staff burnout are prevalent.
The platform also automates the submission of tumor reports to government registries, a legal requirement for cancer centers. Unlike generic AI tools, Triomics' models are specifically trained on oncology data, making them particularly effective for prominent institutions like Memorial Sloan Kettering and Yale Cancer Center.
Despite facing competition from AI medical scribes, Triomics has experienced substantial growth, reporting a fourfold increase in enterprise customers and a tenfold rise in annualized recurring revenue over the past year.
